Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · Feb 18, 2020

Keywords

ClinConnect Summary

The clinical trial titled "Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas" is exploring new ways to understand pancreatic health, especially concerning pancreatic lesions, tumors, and cysts. Researchers at the Florida Pancreas Collaborative are looking for patients who may have these conditions or are experiencing related symptoms. The aim is to collect various types of information—like blood samples, medical images, and surveys—to help create non-invasive diagnostic tools. These tools could make it easier for doctors to personalize treatment decisions based on individual patient needs.

If you are between the ages of 65 and 74 and have been referred to a gastrointestinal clinic or have a suspected or diagnosed pancreatic issue, you may be eligible to participate. It's important that you haven't started any treatment for your pancreatic condition yet. Participants will need to sign a consent form and be willing to provide some medical information and samples during standard care procedures. This study could help improve the way pancreatic conditions are diagnosed and treated in the future, making it a potentially important step in advancing care for patients facing these challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals who present to the GI clinic, surgery, or endoscopy at Moffitt, Florida Research Institute (FRI), or UM with a clinical suspicion for (or diagnosis of) a pancreatic lesion, cyst, mass, cancer, or pancreatitis based on symptoms, imaging, or blood-work and has not had any treatment involving their pancreas.
• • Able to understand and voluntarily sign the informed consent.
• • Willing to complete study questionnaire(s) and donate medical images and/or biological specimens (including blood, cystic fluid, and/or tissue) obtained at the time of standard of care procedures (biopsy, surgery, and venipuncture) after signing the informed consent document
• Exclusion Criteria:
• • No suspicion or diagnosis of a pancreatic lesion, cyst, mass, cancer, or pancreatitis.
• • Has a diagnosis of a pancreatic lesion, cyst, mass, cancer, or pancreatitis and has already undergone treatment involving the pancreas (which may involve surgery, chemo- or immuno-therapy, and/or radiation).
• • Unable to provide informed consent.
• • Unwilling to complete study questionnaire(s) and/or donate biological specimens or images.